Bristol Myers Squibb (BMS) plans to launch schizophrenia drug Cobenfy in the UK next year at a price matching its U.S. list ...

Karuna Therapeutics and Bristol Myers Squibb are winners of the 2025 Gizmodo Science Fair for their research and development ...

The consequences of President Trump's actions on drug pricing continue to play out, with Bristol Myers Squibb insisting it ...

Compared with sham therapy, 12 days of personalized treatment with high-definition transcranial direct current stimulation ...

With a Sept. 29 deadline looming for pharmaceutical companies to adhere to President Donald Trump’s most favored nation drug ...

Schizophrenia care is shifting. In this article, Dr. Stella Sarraf, founder and CEO of Spinogenix, and Dr. David Walling, ...

US pharma major Bristol Myers Squibb revealed plans to launch Cobenfy (xanomeline and trospium chloride) in the UK in 2026.

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter ...

Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and ...

Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride), in the UK in 2026. The UK would be the first country in Europe to make this medicine available for adults living with ...

In spite of these difficulties, the fundamental question is whether BMY's 20% decline in stock price represents a buying ...

Karuna Therapeutics and Bristol Myers Squibb have won the 2025 Gizmodo Science Fair for developing Cobenfy, a novel schizophrenia treatment approved by the FDA.